BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19273341)

  • 21. Adenosine signaling inhibits CIITA-mediated MHC class II transactivation in lung fibroblast cells.
    Fang M; Xia J; Wu X; Kong H; Wang H; Xie W; Xu Y
    Eur J Immunol; 2013 Aug; 43(8):2162-73. PubMed ID: 23681904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of MHC II genes.
    Drozina G; Kohoutek J; Jabrane-Ferrat N; Peterlin BM
    Curr Top Microbiol Immunol; 2005; 290():147-70. PubMed ID: 16480042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis.
    Waldburger JM; Palmer G; Seemayer C; Lamacchia C; Finckh A; Christofilopoulos P; Baeten D; Reith W; Gabay C
    Arthritis Rheum; 2011 Nov; 63(11):3354-63. PubMed ID: 21739421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.
    Zuo J; Hislop AD; Leung CS; Sabbah S; Rowe M
    J Virol; 2013 May; 87(10):5340-50. PubMed ID: 23449805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Syncytium-inhibiting monoclonal antibodies produced against human T-cell lymphotropic virus type 1-infected cells recognize class II major histocompatibility complex molecules and block by protein crowding.
    Hildreth JE
    J Virol; 1998 Dec; 72(12):9544-52. PubMed ID: 9811687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged survival of class II transactivator-deficient cardiac allografts.
    June Brickey W; Felix NJ; Griffiths R; Zhang J; Wang B; Piskurich JF; Itoh-Lindstrom Y; Coffman TM; Ting JP
    Transplantation; 2002 Nov; 74(9):1341-8. PubMed ID: 12451276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
    Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
    Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA.
    Pan H; O'Brien TF; Wright G; Yang J; Shin J; Wright KL; Zhong XP
    J Immunol; 2013 Jul; 191(2):699-707. PubMed ID: 23776173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly efficient peptide binding and T cell activation by MHC class II molecules of CIITA-transfected cells.
    Martinez-Soria E; Siegrist CA; Mach B
    Int Immunol; 1996 Apr; 8(4):543-9. PubMed ID: 8671641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of the 19S proteasomal ATPases with the ATPase-binding domain of CIITA is essential for CIITA stability and MHC class II expression.
    Bhat KP; Truax AD; Brooks JK; Greer SF
    Immunol Cell Biol; 2010; 88(8):807-16. PubMed ID: 20351748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Smad3 protein is involved in TGF-beta inhibition of class II transactivator and class II MHC expression.
    Dong Y; Tang L; Letterio JJ; Benveniste EN
    J Immunol; 2001 Jul; 167(1):311-9. PubMed ID: 11418665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA.
    Celesti F; Gatta A; Shallak M; Chiaravalli AM; Cerati M; Sessa F; Accolla RS; Forlani G
    Front Immunol; 2023; 14():1133177. PubMed ID: 36993983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression.
    Chang CH; Guerder S; Hong SC; van Ewijk W; Flavell RA
    Immunity; 1996 Feb; 4(2):167-78. PubMed ID: 8624807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene.
    Rohn W; Tang LP; Dong Y; Benveniste EN
    J Immunol; 1999 Jan; 162(2):886-96. PubMed ID: 9916712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of PU.1 in MHC Class II Expression via CIITA Transcription in Plasmacytoid Dendritic Cells.
    Miura R; Kasakura K; Nakano N; Hara M; Maeda K; Okumura K; Ogawa H; Yashiro T; Nishiyama C
    PLoS One; 2016; 11(4):e0154094. PubMed ID: 27105023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nitric oxide and KLF4 protein epigenetically modify class II transactivator to repress major histocompatibility complex II expression during Mycobacterium bovis bacillus Calmette-Guerin infection.
    Ghorpade DS; Holla S; Sinha AY; Alagesan SK; Balaji KN
    J Biol Chem; 2013 Jul; 288(28):20592-606. PubMed ID: 23733190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The induction of major histocompatibility complex class II expression is sufficient for the direct activation of human CD4+ T cells by porcine vascular endothelial cells.
    Yun S; Rose ML; Fabre JW
    Transplantation; 2000 Mar; 69(5):940-4. PubMed ID: 10755554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of MHC class I expression by the MHC class II transactivator CIITA.
    Martin BK; Chin KC; Olsen JC; Skinner CA; Dey A; Ozato K; Ting JP
    Immunity; 1997 May; 6(5):591-600. PubMed ID: 9175837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes.
    Villard J; Muhlethaler-Mottet A; Bontron S; Mach B; Reith W
    Int Immunol; 1999 Mar; 11(3):461-9. PubMed ID: 10221658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
    Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
    J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.